Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 394 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Open Angle Clear all

Conditions: Glaucoma, Ocular Hypertension
Interventions: Latanoprostene bunod; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 20 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Glaucoma, Open-Angle
Interventions: Images of eye at 2 eye pressures; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Open-Angle Glaucoma
Interventions: Blood Collection Only; Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Primary Open Angle Glaucoma
Interventions: Hydrus Microstent, Cataract surgery, Monofocal IOL; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 22
States / cities: Irvine, California • Sacramento, California • Loveland, Colorado + 19 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops; Combination Product · Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 36
States / cities: Artesia, California • La Jolla, California • Los Angeles, California + 31 more

Conditions: Open-angle Glaucoma or Ocular Hypertension
Interventions: DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo; Drug · Other
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 7
States / cities: Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more

Conditions: Open-angle Glaucoma
Interventions: Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Vehicle; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Open Angle Glaucoma -Ocular Hypertension
Interventions: Latanoprost, SAR366234; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Inglewood, California • Cape Coral, Florida • Roswell, Georgia + 2 more

Conditions: Primary Open-angle Glaucoma
Interventions: iStent; Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: Not listed
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 18
States / cities: Chico, California • Huntington Beach, California • Napa, California + 15 more

Conditions: Glaucoma
Interventions: Triesence, balanced salt solution BSS; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Open Angle, Low Risk, Ocular Hypertension, Glaucoma Suspect
Interventions: Mercury™ Multi-Pressure Dial (MPD) Experimental Goggle, Mercury™ Multi-Pressure Dial (MPD) Placebo Goggle; Device
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 22 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Glaucoma, Open-Angle
Interventions: Negative Pressure Treatment via the Mercury Multi-Pressure Dial; Device
Lead sponsor: Equinox; Industry
Eligibility: 22 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Chicago, Illinois • Sioux Falls, South Dakota • San Antonio, Texas

Conditions: Glaucoma, Glaucoma Open-Angle
Interventions: Eyetronic rtACS, Sham rtACS; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Active Comparator: Timolol 0.5%, Sham: Applicator Without Needle, Timolol Vehicle (placebo); Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 56
States / cities: Phoenix, Arizona • Glendale, California • Irvine, California + 51 more

Conditions: Glaucoma, Open-Angle
Interventions: H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]; Drug
Lead sponsor: Allysta Pharmaceutical; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Goose Creek, South Carolina

Conditions: Glaucoma, Open-Angle, Chronic Wounds
Interventions: Timolol Maleate; Drug
Lead sponsor: VA Northern California Health Care System; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Mather, California

Conditions: Glaucoma
Interventions: iStent Infinite; Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 35 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Primary Open Angle Glaucoma
Interventions: Canaloplasty using the iTrack microcatheter with Healon GV Pro, Canaloplasty using the Omni surgical system with Healon GV Pro, Canaloplasty using the iTrack microcatheter with Healon Pro, Canaloplasty using the Omni surgical system with Healon Pro; Device
Lead sponsor: Nova Eye, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Glendale, Arizona • Beverly Hills, California • Orange, California + 4 more

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost, Timolol 0.5%, Placebo Ocular Insert, Placebo Eye Drops; Drug · Device
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 10
States / cities: Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 7 more

Conditions: Glaucoma
Interventions: BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Glendale, California • Newport Beach, California • Pasadena, California + 11 more

Conditions: Open Angle Glaucoma
Interventions: Transluminal viscoelastic delivery and trabeculotomy; Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 15
States / cities: Dothan, Alabama • Lake Havasu City, Arizona • Fayetteville, Arkansas + 12 more

Conditions: Healthy Volunteers
Interventions: 13mg Bimatoprost Ocular Insert; Drug
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Artesia, California

Search by objective public record fields.

Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT

Optic Nerve Head Strain as Biomarker for Glaucoma

Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)

Hydrus® Microstent New Enrollment Post-Approval Study

Clinical Study Comparing Two Models of a Travoprost Intraocular Implant

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma

28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry

Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?

Effect of Negative Pressure on Pattern Electroretinography Readings

Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma

Electrical Stimulation for Vision Neuroenhancement in Glaucoma

The Effect of Omega-3 Fatty Acid Supplementation on Intraocular Pressure & Ocular Surface

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

H-1337 Ophthalmic Solution Phase 1/2

Absorption and Safety of Topical Timolol to Treat Chronic Wounds

Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

Multicenter Ab-interno Glaucoma Study Investigating Canaloplasty

Dose-Ranging Study of the Bimatoprost Ocular Insert

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

Study of OMNI System in OAG (GEMINI)

Bimatoprost Ocular Insert Pharmacokinetic Study